Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
CASI Pharmaceuticals, Inc. clinical trials
Also known as EntreMed.
The registry lists 24 studies whose lead sponsor is CASI Pharmaceuticals, Inc. or one of 1 company grouped under it. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jul 22, 2026.
Keep track of what changes. Save the CASI Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to CASI Pharmaceuticals, Inc..
- CASI Pharmaceuticals, Inc.22 studiesSame company
Something wrong?
- CASI pharmaceuticals, Inc.1 studySame company
Something wrong?
- CASI Pharmaceuticals (China) Co., Ltd.1 study →Regional office
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- A Two Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection (ABMR).RecruitingNCT07641426Phase 1/2
Sponsor listed in the registry: CASI pharmaceuticals, Inc.
- A Dose-escalation Study Followed by a Dose Optimal Study to Evaluate the Safety and Efficacy of CID-103 in Adults With Chronic Immune ThrombocytopeniaRecruitingNCT07017725Phase 1/2
- A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar CarcinomaCompletedNCT02234986Phase 2
- CID-103 (Anti-CD38 Antibody) in Previously Treated Relapsed or Refractory Multiple MyelomaCompletedNCT04758767Phase 1
- Evaluate Safety and Efficacy of High-dose Melphalan HCL for Injection in MM Patients With Auto-HSC TransplantationCompletedNCT06425276Phase 4
Sponsor listed in the registry: CASI Pharmaceuticals (China) Co., Ltd.
- Study of ENMD-2076 in Patients With Multiple MyelomaCompletedNCT00806065Phase 1
- A Dose-Escalation Study of ENMD-2076 Administered Orally to Patients With Advanced CancerCompletedNCT00658671Phase 1
- Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBCCompletedNCT01639248Phase 2
- Study of Oral ENMD-2076 Administered to Patients With Ovarian CancerCompletedNCT01104675Phase 2
- Safety Study of MKC-1 Combined With Pemetrexed to Treat Advanced Cancer and Non-Small Cell Lung CancerCompletedNCT00408226Phase 1/2
- A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial CancerCompletedNCT00607607Phase 2
- Phase 2 Study of Panzem® NCD Alone and Combined With Sunitinib Malate in Patients With Metastatic Renal Cell CarcinomaCompletedNCT00444314Phase 2
- Phase 2 Study of Oral MKC-1 in Patients With Unresectable or Metastatic Pancreatic CancerCompletedNCT00568646Phase 2
- Study of ENMD-2076 in Patients With Relapsed or Refractory Hematological MalignanciesCompletedNCT00904787Phase 1
- A Combination Study to Determine the Safety and Efficacy of Panzem NCD With Avastin in Metastatic Carcinoid TumorsCompletedNCT00328497Phase 2
- Phase 1 Study of MKC-1 in Patients With Advanced CancerCompletedNCT00656461Phase 1
- A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1CompletedNCT00306631Phase 2
- A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic MalignanciesCompletedNCT00506402Phase 1
- A Phase 2 Study With Panzem in Patients With Relapsed or Plateau Phase Multiple MyelomaCompletedNCT00592579Phase 2
- Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung CancerCompletedNCT00049790Phase 2
- Safety and Efficacy Study of Panzem NCD to Treat GlioblastomaCompletedNCT00306618Phase 2
- Safety and Efficacy Study of Panzem® Nanocrystal Colloidal Dispersion in Patients With Ovarian CancerCompletedNCT00400348Phase 2
- Efficacy and Pharmacodynamic Study of Panzem® NCD in Patients With Hormone-Refractory Prostate CancerCompletedNCT00394810Phase 2
- Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)CompletedNCT00481455Phase 2